Acadia Healthcare Company, Inc. (ACHC) - 10-K Summary
Business Context and Reporting Period
Company: Acadia Healthcare Company, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Acadia is the leading publicly traded pure-play provider of behavioral healthcare services in the U.S. As of December 31, 2024, the company operated 262 facilities with approximately 11,850 beds across 39 states and Puerto Rico. The company focuses on high-acuity and complex needs patient populations through acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers (CTCs), and residential treatment centers.
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 |
|---|---|---|
| Revenue | $3,154.0 | $2,928.7 |
| Net Income (Attributable to Acadia) | $255.6 | $(21.7) |
| Net Income Margin | 8.1% | (0.8%) |
| Operating Cash Flow | $129.7 | $462.3 |
| Total Debt (Net of issuance costs) | ~$2,000.0 | ~$1,371.8 |
| Cash and Cash Equivalents | $76.3 | $100.1 |
| Capital Expenditures | $690.4 | $424.1 |
| Consolidated Total Net Leverage Ratio | 2.7x | N/A |
Note: 2023 Net Income was significantly impacted by a $394.2 million legal settlement expense related to the Desert Hills Litigation.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 7.7% year-over-year to $3.15 billion, driven by a 3.2% increase in same-facility patient days and a 4.3% increase in revenue per patient day.
- Profitability Recovery: The company returned to profitability with $255.6 million in net income, compared to a net loss of $21.7 million in 2023. The 2023 loss was primarily due to the $394.2 million Desert Hills settlement expense, which did not recur in 2024.
- Debt Expansion: Total debt increased significantly due to the incurrence of $350.0 million in Incremental Term Loans in January 2024 and net borrowings of $290.0 million on the Revolving Facility during the year.
- Cash Flow Decline: Operating cash flow decreased to $129.7 million from $462.3 million in 2023. This decline was primarily due to the $400.0 million cash payment made in January 2024 to settle the Desert Hills Litigation.
- Capital Expenditures: CapEx increased to $690.4 million (up from $424.1 million), with $586.4 million allocated to expansion projects, reflecting the company's strategy to add beds and open new facilities.
Guidance, Outlook, and Risks
Management Commentary & Strategy: Management continues to pursue five growth pathways: expansions of existing facilities, joint venture partnerships, de novo facilities, acquisitions, and expansion across the continuum of care. In 2024, the company added 776 beds (312 to existing facilities and 464 via new facilities/CTCs). The company is nearing completion of a syndication process to replace its current Credit Facility with a new $1.0 billion revolving facility and $650 million term loan.
Share Repurchase Program: On February 25, 2025, the Board authorized a new $300.0 million share repurchase program with no termination date.
Key Risks and Contingencies:
- Legal Proceedings: While the Desert Hills Litigation was settled for $400.0 million in early 2024, a sixth lawsuit based on similar facts has been filed, and the company cannot estimate the ultimate liability. Additionally, the company is subject to ongoing government investigations (DOJ, SEC) regarding admissions, length of stay, and billing practices, with no ability to estimate potential liability at this time.
- Regulatory Environment: The company faces significant risks related to compliance with the Anti-Kickback Statute, Stark Law, and False Claims Act. Changes in Medicaid/Medicare reimbursement rates or policies could materially impact revenue.
- Debt Servicing: With approximately $2.0 billion in debt, the company is subject to restrictive covenants. Servicing this debt requires significant cash flow, and the company is exposed to interest rate fluctuations on its variable-rate debt.
- Human Capital: The company faces competition for staffing, labor shortages, and rising wage inflation, which could increase operating costs and reduce profitability.
Investor Verification Checklist
- Desert Hills Litigation Status: Verify the status of the sixth lawsuit filed in January 2024 and any potential exposure beyond the $400 million settlement.
- Government Investigations: Monitor updates on the DOJ and SEC investigations regarding billing practices and admissions, as the company currently cannot estimate the financial impact.
- Debt Refinancing: Confirm the closing of the proposed "Replacement Credit Facility" ($1.65 billion total) and the terms associated with the new debt structure.
- Capital Allocation: Assess the impact of the new $300 million share repurchase program on liquidity, given the high capital expenditure requirements for expansion.
- Payor Mix Trends: Review the shift in revenue mix, noting that Medicaid now represents 56.5% of revenue (up from 53.9% in 2023), increasing sensitivity to state budgetary pressures.